Table 3:

HPV testing and histologic outcomes of Pap tests from transmasculine individuals receiving testosterone from this cohort and the literature

Study	Current study		Adkins et al (2018)		Williams et al (2020)	Plummer et al (2021)
	Cytology	Histology	Cytology	Histology	Cytology*	Cytology	Histology
HPV-positive cases	2 NILM	1 benign/1 no FU	1 NILM	1 benign	1 NILM	4 NILM	1 benign/3 no FU
	2 ASC-US	2 HSIL	1 ASC-US/1 ASC-H	1 no FU/1 LSIL		1 ASCUS	1 LSIL
	2 HSIL	2 HSIL	1 HSIL	1 HSIL
HPV-negative cases	22 NILM	12 benign/10 no FU	6 NILM	6 benign	3 NILM	16 NILM	6 benign/10 no FU
	1 ASC-US	1 benign	2 ASC-US	2 benign	1 ASC-US	2 ASC-US/1 AGC	2 benign/1 LSIL
	3 UNSAT	1 benign/2 no FU				4 UNSAT	4 benign
HPV-positive rate	6/32 (19%)		4/12 (33%)		1/5 (20%)	5/27 (18.5%)

^*no histologic outcome available according to HPV testing;

NILM: negative for intraepithelial lesion or malignancy; FU: follow-up; ASCUS: atypical squamous cells of undetermined significance; HSIL: high-grade squamous intraepithelial lesion; LSIL: low-grade squamous intraepithelial lesion; ASC-H: atypical squamous cells of undetermined significance, cannot rule out HSIL; AGC: atypical glandular cells; UNSAT: unsatisfactory